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ABSTRACT
Objective To determine the effectiveness and safety of
nicotine replacement therapy assisted reduction to stop
smoking.
DesignSystematicreviewofrandomisedcontrolledtrials.
Data sources Cochrane Library, Medline, Embase,
CINAHL, PsychINFO, Science Citation Index, registries of
ongoing trials, reference lists, the drug company that
sponsored most of the trials, and clinical experts.
Review methods Eligible studies were published or
unpublished randomised controlled trials that enrolled
smokerswhodeclarednointentiontoquitsmokinginthe
short term, and compared nicotine replacement therapy
(with or without motivational support) with placebo, no
treatment, other pharmacological therapy, or
motivational support, and reported quit rates. Two
reviewers independently applied eligibility criteria. One
reviewer assessed study quality and extracted data and
these processes were checked by a second reviewer. The
primary outcome, six months sustained abstinence from
smoking beginning during treatment, was assessed by
individual patient data analysis. Other outcomes were
cessation and reduction at end of follow-up, and adverse
events.
Data synthesis Seven placebo controlled randomised
controlled trials were included (four used nicotine
replacement therapy gum, two nicotine replacement
therapy inhaler, and one free choice of therapy). They
were reduction studies that reported smoking cessation
as a secondary outcome. The trials enrolled a total of
2767 smokers, gave nicotine replacement therapy for
6-18 months, and lasted 12-26 months. 6.75% of
smokers receiving nicotine replacement therapy attained
sustained abstinence for six months, twice the rate of
those receiving placebo (relative risk (fixed effects) 2.06,
95% confidence interval 1.34 to 3.15; (random effects)
1.99,1.01to3.91;fivetrials).Thenumberneededtotreat
was 29. All other cessation and reduction outcomes were
significantly more likely in smokers given nicotine
replacement therapy than those given placebo. There
were no statistically significant differences in adverse
events (death, odds ratio 1.00, 95% confidence interval
0.25 to 4.02; serious adverse events, 1.16, 0.79 to 1.50;
and discontinuation because of adverse events, 1.25,
0.64 to 2.51) except nausea, which was more common
with nicotine replacement therapy (8.7% v 5.3%; odds
ratio 1.69, 95% confidence interval 1.21 to 2.36).
Conclusions Available trials indicate that nicotine
replacement therapy is an effective intervention in
achievingsustainedsmokingabstinenceforsmokerswho
havenointentionorareunabletoattemptanabruptquit.
Most of the evidence, however, comes from trials with
regular behavioural support and monitoring and it is
unclear whether using nicotine replacement therapy
without regular contact would be as effective.
INTRODUCTION
Smokingisoneofthegreatestcausesofillnessandpre-
mature death in developed and developing countries,
but giving up smoking can prevent most of the harm.
AlthoughnearlyhalfofallsmokersintheUnitedKing-
dom try to stop every year, only 2-3% succeed.
1 One
reason for the low success is that many quit attempts
areunplanned
2sothatthemosteffectivecessationaids
maynotbeused.
1Themostwidelyusedcessationaidis
nicotine replacement therapy.
1 Standard instructions
forusingsuchtherapyandguidancefromtheNational
Institute for Health and Clinical Excellence require
smokers to set a day when they will abruptly stop
smoking and use nicotine replacement therapy or
other pharmacotherapy as a substitute for smoking.
Despite 70% of smokers wanting and intending to
stopatsometime,
3only12%arereadytostopsmoking
in the next month
4 and thus only this small proportion
are suitable for abrupt quit interventions.
IntheUKthelicenceforsomenicotinereplacement
therapies (gum, inhaler, and, most recently, lozenge)
has been extended to allow longer term use in those
who are not willing or able to quit abruptly, thereby
aidingthemtocutdownsmokingandtofacilitatequit-
ting. This is termed nicotineassisted reduction to stop;
also called cut down then stop,
5 cut down to stop, and
cutdowntoquit.Wecarriedoutasystematicreviewof
randomised controlled trials to determine the effec-
tiveness of nicotine assisted reduction to stop and
whether there are associated harms. Unlike previous
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67 which reported only point prevalence of
cessation at end of follow-up, we focused on sustained
cessation from smoking, widely considered the super-
ior outcome measurefor effectiveness.
89Thiswas pos-
sible because of access to unpublished trial reports.
This review is an updated extension and summary of
our Health Technology Assessment on this topic.
10
An ancillary paper will report on an economic ana-
lysis to determine whether nicotine assisted reduction
to stop provides good value for money from the per-
spective of the UK National Health Service.
METHODS
We electronically searched the Cochrane library,
Medline, Embase, CINAHL, PsychINFO, and
ScienceCitationIndexfromatleast1992toNovember
2007forrelevanttrials,usingacombinationoffreetext
and MeSH terms (see web extra appendix 1). We con-
tacted authors, experts, and the pharmaceutical com-
panythatsponsoredmosttrials,andcheckedreference
lists of retrieved documents for further trials. All titles
and abstracts were screened for relevance and we
obtained the full paper if appropriate.
Studieswere includedinthereviewif theywereran-
domised controlled trials meeting the following cri-
teria:
 The population comprised smokers who were
unable or unwilling to stop abruptly
 The intervention was gum or inhaler nicotine
replacement therapy alone or as part of
combination therapy, such as motivational
support. Some studies considered nicotine
replacement therapy as a generic intervention
and allowed a choice, and such studies were
considered to meet the inclusion criteria
irrespective of whether data could be
disaggregated for different forms of therapy (the
licensing of lozenges for gradual smoking
cessation coincided with the latter stages of this
review and is not dealt with specifically here)
 The comparator was placebo, no treatment, non-
nicotine replacement therapy drugs for smoking
cessation, or psychological interventions, such as
motivational support. If the intervention arm
included an adjunct therapy the comparator had
to include one too
 The outcome was abstinence from smoking.
The criteria were applied independently by two
reviewers and discrepancies resolved by discussion
and with the involvement of a third reviewer if
required.
Data extraction and quality assessment
Thequalityofincludedstudieswasassessedaccording
tostandardguidelines
11anddataextractedusingadata
extraction form. Both tasks were undertaken by one
reviewer and checked for accuracy by a second. Dis-
agreements were resolved by discussion, and with a
third reviewer if necessary. When information was
missing it was sought from the authors or sponsors of
trials.
Data synthesis
Studies were grouped according to outcome and com-
parison groups. The primary outcome for the review
wassix months’sustainedabstinencestartinganytime
before the end of treatment. We regard this as defini-
tive evidence of the effectiveness of treatment.
89Sec-
ondary outcomes were point prevalence abstinence at
end of follow-up; sustained abstinence from early in
treatment to end of follow-up; sustained reduction
from week 6 to end of follow-up; point prevalence
reduction at end of follow-up; and adverse events
throughout follow-up—death, serious adverse events
(death,admissiontohospital,orpermanentdisability),
discontinuationowingtosideeffects,andnausea(asan
index symptom of possible nicotine overdose).
Meta-analysis was carried out using Stata (version
10). For smoking outcomes we summarised data with
relative risks; the preferred statistic of the Cochrane
TobaccoAddictionReviewGroup.Foradverseevents
wesummariseddatausingPetooddsratio,whichisthe
preferred statistic for rare occurrences.
12
Developing a measure of sustained abstinence
Inmoststudiesonsmokingcessationallindividualsset
a quit day near the beginning of the study and once
they relapse they are counted forever as a sustained
abstinence failure, even if they subsequently make a
quitattemptandsucceed.Instudiesofnicotineassisted
reduction to stop, participants have the opportunity to
use nicotine replacement therapy for a prolonged per-
iod (up to 18 months) during which time they make
several quit attempts. Unlike normal studies on cessa-
tion,wheretheindexquitattemptisthefirst,in studies
on nicotine assisted reduction to stop, treatment con-
tinues whether or not someone attempted to stop and
failed. Thus, previous failures do not nullify later suc-
cess. We counted the number who had started to
abstain during treatment and had maintained absti-
nence for at least six months. Some smokers started
quit attempts late in the treatment and because fol-
low-up did not continue for six months beyond the
end of the treatment, follow-up ceased with these peo-
ple having been abstinent continuously for several
months, but fewer than six months. To count them as
Articles identified from electronic searches (n=6152)
Potentially relevant full texts obtained (n=138):
  Peer reviewed publications (n=131)
  Unpublished trial reports (n=7)
Included studies (in 12 articles) (n=7):
  One study in two publications
  Four studies each in one publication plus one
    unpublished trial report
  Two studies each in one unpublished trial report
Excluded articles (n=126):
  Peer reviewed publications (n=125)
  Unpublished trial reports (n=1)
Fig 1 | Flow of papers through study
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Reference,
country, trial
dates
Treatment
duration;
follow-up
(months) Indication
Noingroup,
meanagein
years (%
female)
Baseline
cigarettes
smoked/day,
exhaled carbon
monoxide level
(ppm),
Fagerström
score*
NRT
inter-
vention†
(nicotine
content)
Compara-
tor
Other
treatment
compo-
nents Main outcomes measured
Funding
(trial
code) NRT
Con-
trol NRT Control
Batra,
w1
Germany and
Switzerland
(NR)
12; 13 Not intending to
quitinnextmonth;
willing to change
behaviour
184,
42.6
(45.9)
180,
43.5
(35.2)
27.9,
29.1, 5.7
29.6,
28.2, 5.9
Gum (4 mg)
for
12 months
Placebo
gum for
12 months
Clinic visits
(n=9),
telephone
support,
additional
clinic visits
as necessary
Smoking reduction; abstinence
(exhaledcarbonmonoxidelevel
<10 ppm)‡; NRT use (self report
and records); serum cotinine
and thiocyanate levels (ppm);
adverseevents;haematological
risk factors§
Industry
(980-CHC
1013-
028)
Bolliger,
w2
Sweden and
Switzerland
(Feb 1997 to
May 1999)
18; 24 Unwilling or
unable to quit;
wanted to reduce
cigarette
consumption
200,
46.4
(57)
200,
45.8
(48)
28.2,
27.1, 5.5
30.3,
27.1, 5.6
Inhaler
(10 mg)¶ for
18 months
Placebo
inhaler as
required
Clinic visits
(n=9)
Smoking reduction; abstinence
(exhaledcarbonmonoxidelevel
<10ppm)‡;NRTuse(selfreport),
acceptability; plasma cotinine
and thiocyanate levels, (ppm);
quality of life** and adverse
events; haematological risk
factors§
Industry
(96-NNIN
016)
Haustein,
w3
unpub-
lished††,
Germany(Mar
2000 to Nov
2001)
9; 12 Not intending to
quit in next month
want to reduce
cigarette
consumption
97,
42.3
(50)
96,
41.7
(50)
24.3,
27.5, 5.4
24.4,
28.9, 5.5
Gum (4 mg)
as required
for 9 months
Placebo
gum as
required
for
9 months
Clinic visits
(n=8)
Smoking reduction; abstinence
(exhaledcarbonmonoxidelevel
<10 ppm); product use; change
in Fagerström score; adverse
events
Industry
(980 CHC-
9021-
0013)
Rennard,
w4
USA (Feb
2000 to Apr
2001)
12; 15 Not intending to
quit within next
month, wanted to
reduce cigarette
consumption
215,
45.9
(59)
214,
44.8
(54)
29.3,
29.7, 6.5
30.4,
29.5, 6.6
Inhaler
(10 mg) for
12 months
Placebo
inhaler for
12 months
Clinic visits
(n=9)
Smoking reduction; abstinence
(exhaledcarbonmonoxidelevel
<10ppm)‡;NRTuse(selfreport),
acceptability; plasma cotinine
and thiocyanate levels (ppm);
quality of life‡‡ and adverse
events; haematological risk
factors§
Industry
(98-NNIN-
027)
Wennike,
w5
Denmark (Feb
1999 to May
2000)
12; 24 Not intending to
quit within next
month, wanted to
reduce cigarette
consumption
205,
45(65)
206,
44(59)
24, 29,
6.4
24, 27,
6.4
Gum (2 or
4m g ;
depending
on
Fagerström
score) for
12 months
Placebo
gum for
12 months
Clinic visits
(n=9)
Smoking reduction; abstinence
(exhaledcarbonmonoxidelevel
<10 ppm)‡; NRTuse (selfreport)
and compliance; plasma
cotinineand thiocyanatelevels;
quality of life** and adverse
events; haematological risk
factors§
Industry
(98NNCG-
014)
Wood-
Baker,
w6
unpublished,
Australia (Jun
1999 to Mar
2001)
12; 15 Not intending to
quit within next
month, wanted to
reduce cigarette
consumption
218,
42.9
(54)
218,
45.3
(55)
29.0,
25.8, 6.6
27.4,
25.9, 6.4
Gum (2 or
4m g ;
depending
on
Fagerström
score) for
12 months
Placebo
gum for
12 months
Clinic visits
(n=9)
Smoking reduction; abstinence
(exhaledcarbonmonoxidelevel
<10 ppm)‡;N R Tu s ea n d
compliance; plasma cotinine
and thiocyanate levels; quality
of life** and adverse events;
haematological risk factors§
Industry
(98NNCG-
017)
Etter,
w7
Switzerland
(1999 to
2002)§§
6¶¶; 26 Not intending to
quit within next
6 months, wanted
toreducecigarette
consumption
265, 269, 389;
43.2,41.7,42.9;
(46, 51, 56)
29.8, 29.4, 30.2; NR,
NR, NR; 6.0, 5.9, 6.2
Free
choice***:
inhaler
(10mg),gum
(4 mg), or
patch
(25 mg) for
6 months
Placebo
NRT for
6 months
and no
inter-
vention
Literature
only
Smoking reduction;
abstinence†††; product use;
change in Fagerström score;
adverse events
Govern-
ment and
industry
(no trial
code)
NR=not reported; NRT=nicotine replacement therapy.
*Test for nicotine dependence.
†Gum and inhaler were Nicorette products (Pharmacia).
‡Seven day point prevalence.
§Examples include C reactive protein, fibrinogen, white blood cell count.
¶Total available nicotine 4-5 mg.
**Short form 36.
††This study had two further arms that compared short term quit intervention using gum with placebo.
‡‡Revised RAND 36 item health survey 1.0.
§§This study had a third arm in which participants received no treatment.
¶¶Quitters continued to receive NRT after six months.
***Switching between products was allowed.
†††Point prevalence for past seven days and one month.
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so we developed a method to determine what propor-
tion of these would sustain abstinence of six months if
follow-uphadbeenlongenough.Weappliedtheprob-
ability that a smoker who abstained for x months
wouldgoontoabstainforsixmonthstothosesmokers
who were abstinent for x months at the end of study.
This calculation was based on probabilities derived
from analyses using individual person data of all quit
attempts made in each of the studies for which indivi-
dual person data were available (see web extra appen-
dix 2).
RESULTS
Figure1showstheflowofpapersthroughthesystema-
tic review. Seven randomised controlled trials
w1-w7 (12
articles) met the inclusion criteria (see web extra
appendix 3 for excluded articles).
Table 1 shows the characteristics of the included
studies. Six of the randomised controlled trials were
sponsored by industry,
w1-w6 two of which were unpu-
blished.
w3 w6 Full, unpublished trial reports were
obtained for all six trials, of which five reports
w1 w3-w6
contained individual patient data allowing calculation
of at least six months’ sustained abstinence. The
seventh trial
w7 was independent, and unpublished
data were obtained from the authors.
All the studies recruited smokers who were unwill-
ing or unable to quit abruptly, and none emphasised
reduction then stop on recruitment. Consequently the
primary outcome was reduction and not cessation.
Trial design
All the studies were randomised parallel group trials
with nicotine replacement therapy and placebo arms.
Onetrial
w3randomisedpeopletofourarms;twoofthe
arms were not included in this review because partici-
pants were randomised to reduction over only one
month (with active nicotine replacement therapy or
placebo). Another trial
w7 had three arms, comprising
no pharmacotherapy, placebo, and nicotine replace-
menttherapy.Forconsistencyweanalyseddifferences
between nicotine replacement therapy and placebo.
Population
The populations had similar personal and smoking
characteristics typical of heavy smokers attending
smoking cessation clinics. Potential participants with
heart disease, those receiving psychiatric drugs, preg-
nant or lactating women, or people with other drug
problems were excluded. Recruitment was by adver-
tisement.
Intervention
Four trials used gum,
w1 w3 w5 w6 two used inhalers,
w2 w4
and one used free choice of gum, inhaler, or patch.
w7
Prior to randomisation in two trials,
w5 w6 smokers were
stratified by nicotine dependence (Fagerström score);
the less nicotine dependent were given 2 mg gum
whereas the more dependent received 4 mg gum.
The other gum trials used 4 mg gum. The trial with
three arms
w7 used a 15 mg/16 hour patch, 4 mg gum,
or inhaler.
Nicotine replacement therapy was available for six
months in one trial
w7 (although people who remained
abstinent could have extended use). The other trials
provided nicotine replacement therapy for nine
months,
w3 12 months,
w1 w4-w6 and 18 months.
w2
Behavioural support
The trial with three arms
w7 had no clinic visits and no
behavioural support, but participants received a 20
page booklet covering reasons for reducing cigarette
consumptionandthemethodsforachievingreduction.
In the other publications behavioural support was
described as moderate (visits lasting 15-30 minutes
w5),
or participants were “instructed to reduce their smok-
ing . . . and provided with ways to do so,”
w4 or
Table 2 |Summary of quality assessment of included randomised controlled trials
Study
Was assignment of treatment
really random?
Was allocation concealed and
concealment method described?
Were groups
similar at
baseline?
Were
eligibility
criteria
specified?
Who was blinded to treatment
allocation?
Was intention to
treat analysis
used and were
drop outs
accounted for?
Batra
w1 Yes; computer generated list Yes; sealed envelopes Yes* Yes Participants, therapists, and
outcome assessors
Yes, yes
Bolliger
w2 Yes; computer generated list Yes; sealed envelopes Yes* Yes Participants, therapists, and
outcome assessors
Yes, yes
Haustein
w3 Yes; computer generated list Yes; sealed envelopes Yes Yes Participants, therapists, and
outcome assessors
Yes, yes
Rennard
w4 Likely, but method not described Likely, but method not reported Yes Yes Participants, therapists, and
outcome assessors
Yes, yes
Wennike
w5 Yes (stratified by Fagerström
score); computer generated list
Yes; sealed code list Yes* Yes Participants, therapists, and
outcome assessors
Yes, yes
Wood-Baker
w6 Yes (stratified by Fagerström
score); computer generated list
Yes; sealed envelopes Yes Yes Participants, therapists, and
outcome assessors
Yes, yes
Etter
w7 Yes; computer generated list Unclear Yes Yes Participants and outcome
assessors
Most outcomes†,
yes
When extensive unpublished study reports were available, they were used for quality analysis.
*Except for small imbalance in sex distribution.
†Not intention to treat for product usage and for completeness of blinding of participants (determined at six months).
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Gum
  Batra (13)
w1
  Haustein (12)
w3
  Wennike (24)
w5
  Wood-Baker (15)
w6
Inhaler
  Rennard (15)
w4
Subtotal: I2=52.4%, P=0.078
Abstinence from week 6 to end of follow-up
Gum
  Batra (13)
w1
  Haustein (12)w3
  Wennike (24)w5
  Wood-Baker (15)w6
Inhaler
  Bolliger (24)
w2
  Rennard (15)
w4
Mixed
  Etter (26)
w7
Subtotal: I2=0.0%, P=0.841
Point prevalence of abstinence at end of follow-up
Gum
  Batra (13)w1
  Haustein (12)
w3
  Wennike (24)
w5
  Wood-Baker (15)
w6
Inhaler
  Bolliger (24)
w2
  Rennard (15)
w4
Mixed
  Etter (26)
w7
Subtotal: I
2=44.8%, P=0.093
Reduction from week 6 to end of follow-up
Gum
  Batra (13)
w1
  Haustein (12)w3
  Wennike (24)w5
  Wood-Baker (15)
w6
Inhaler
  Bolliger (24)
w2
  Rennard (15)w4
Subtotal: I2=0.0%, P=0.604
Point prevalence of reduction at end of follow-up
Gum
  Batra (13)w1
  Haustein (12)
w3
  Wennike (24)
w5
  Wood-Baker (15)
w6
Inhaler
  Bolliger (24)
w2
  Rennard (15)
w4
Mixed
  Etter (26)
w7
Subtotal: I
2=36.4%, P=0.151
7.83 (1.83 to 33.55)
2.64 (0.72 to 9.65)
2.64 (1.20 to 5.82)
1.00 (0.36 to 2.80)
1.00 (0.42 to 2.34)
2.06 (1.34 to 3.15)
4.89 (0.24 to 101.19)
4.95 (0.24 to 101.75)
13.06 (0.74 to 230.39)
1.00 (0.06 to 15.89)
4.00 (0.45 to 35.47)
4.98 (0.24 to 103.06)
1.69 (0.41 to 7.01)
3.44 (1.48 to 7.96)
2.69 (1.23 to 5.88)
1.36 (0.57 to 3.23)
2.73 (1.17 to 6.35)
2.33 (0.61 to 8.91)
1.24 (0.67 to 2.27)
5.64 (1.68 to 18.97)
1.12 (0.70 to 1.80)
1.72 (1.31 to 2.26)
2.93 (1.09 to 7.91)
12.87 (0.73 to 225.29)
13.06 (1.72 to 98.94)
1.50 (0.25 to 8.89)
3.17 (1.29 to 7.76)
3.73 (1.26 to 11.06)
3.84 (2.32 to 6.35)
1.63 (1.12 to 2.38)
1.48 (0.80 to 2.74)
1.51 (0.89 to 2.57)
0.61 (0.34 to 1.08)
1.20 (0.85 to 1.68)
1.46 (0.94 to 2.27)
1.43 (1.07 to 1.90)
1.32 (1.14 to 1.54)
16/184
8/97
21/205
7/218
10/215
62/919
2/184
2/97
6/205
1/218
4/200
2/215
5/265
22/1384
22/184
11/97
19/205
7/218
21/200
17/215
32/265
129/1384
15/184
6/97
13/205
3/218
19/200
15/215
71/1119
55/184
21/97
30/205
17/218
55/200
41/215
83/265
302/1384
0.05 0.25 1 5 20 50
Study (follow-up, months)
Favours
placebo
Favours nicotine
replacement therapy
Relative risk
(95% CI)
Relative risk
(95% CI)
Treatment
2/180
3/96
8/206
7/218
10/214
30/914
0/180
0/96
0/206
1/218
1/200
0/214
3/269
5/1383
8/180
8/96
7/206
3/218
17/200
3/214
29/269
75/1383
5/180
0/96
1/206
2/218
6/200
4/214
18/1114
33/180
14/96
20/206
28/218
46/200
28/214
59/269
228/1383
Control
No of events/No in group
6.73
10.04
26.57
23.30
33.37
100.00
7.24
7.19
7.14
14.32
14.32
7.17
42.62
100.00
10.80
10.74
9.32
4.01
22.70
4.01
38.43
100.00
27.23
2.71
5.37
10.77
32.32
21.60
100.00
14.63
6.17
8.75
12.28
20.17
12.31
25.68
100.00
Weight
(%)
Fig 2 | Meta-analysis of smoking outcomes. Pooled estimates are Mantel Haenszel relative risks (fixed effects). Heterogeneity
statistic Q for at least six months’ abstinence was 8.4 (P=0.078), for abstinence from week 6 to end of follow-up was 2.74
(P=0.840), for point prevalence of abstinence at end of follow-up was 10.86 (P=0.093), for reduction from week 6 to end of
follow-up was 3.63 (P=0.604), and for point prevalence of reduction at end of follow-up was 9.43 (P=0.151)
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w1 w2 The
unpublished trial reports,
w1-w6 however, indicated that
the behavioural support programme was similar in all
these studies. Participants were given a sheet of paper
with written advice on how to use gum or inhaler to
reduce or stop smoking. Clinic staff followed a written
behavioural support protocol giving information on
how much nicotine replacement therapy to use and
how to use it to substitute for cigarettes. In addition,
at each visit the therapist elicited problems from the
participants, helped them find solutions, and related
their progress back to their goals negotiated at the
start of the programme. Smokers were encouraged to
quit during the study. At six and nine months, partici-
pants were instructed to stop smoking completely,
regardless of reduction achieved to that point. At all
visits smoking status was monitored, exhaled carbon
monoxide recorded, and feedback given on progress
towards agreed goals. Typically, behavioural support
and clinic visits were repeated on five or more occa-
sions up to at least a year and in some trials beyond,
to 18 or 24 months.
Outcomes
Theprimaryoutcomeinthetrialswassustainedreduc-
tion. In the industry sponsored trials
w1-w6 sustained
reduction was defined as reported cigarette consump-
tion of less than 50% of baseline from week 6 to week
16, although in some trials this was also to later visits.
Sustained reduction was measured by self reported
cigarettes smoked a day and validated by the carbon
monoxide level that was at least 1 ppm less than at
baseline on each occasion it was checked. The second-
ary outcomes were prolonged abstinence from the
week 6 visit to end of follow-up and 7 day point pre-
valence abstinence and point prevalence of reduction
at various follow-up times.
Inthetrialwiththreearms,
w7pointprevalenceabsti-
nence and point prevalence reduction for the past
seven days and four weeks were the main outcomes
at six and 26 months.
Quality of included studies
Table 2summarisesthequalityoftheincludedstudies.
All were of high quality.
Although trials blinded participants to allocation, it
isdifficulttoblindpeopletopsychoactivedrugs.Atsix
months, participants in the three arm trial
w7 guessed
more accurately than would be expected by chance
whether they had received active drug or placebo.
Sustained six months’ abstinence
Individual person data were available from one trial
using inhaler
w4 and four using gum
w1 w3 w5 w6 and
allowed the calculation and meta-analysis of sustained
abstinence of at least six months.
w1 w3-w6 The propor-
tion of smokers achieving sustained abstinence at six
monthswithnicotinereplacementtherapywasdouble
that with placebo (relative risk 2.06, 95% confidence
interval 1.34 to 3.15; fig 2), but the rates were low
(6.75%v3.28%,respectively).Moderateheterogeneity
was suggested (χ
2=8.4, df=4, P=0.08, I
2=53%). There
was no evidence to indicate that this was due to the
type of nicotine replacement therapy used, and the
inclusion criteria and protocols of the trials were simi-
lar. By a random effects model the relative risk was
1.99 (1.01 to 3.91).
Other smoking outcomes
Sustained abstinence was measured from six weeks
(two weeks in one study
w1) to the end of follow-up.
Point prevalence abstinence was also measured at last
follow-up, which was one month,
w1 three months,
w3 w4
w7sixmonths,
w212months,
w5and20months
w7afterthe
endoftreatment.Sustainedreductionandpointpreva-
lencereductionwasmeasuredatthesetimepointsdur-
ing treatment and at follow-up. Figure 2 summarises
these results.
As might be expected of smokers unwilling or
unable to quit in the short term, sustained abstinence
rates starting from six weeks were low; across all stu-
dies 1.6% in the nicotine replacement therapy group
and 0.4% in the placebo group. Point prevalence
rates of abstinence at the end of follow-up were 9.3%
and 5.4%, respectively.
Successful reduction was more common. In those
receiving active nicotine replacement therapy, 21.8%
had reduced consumption by more than 50% at final
follow-up compared with 16.5% receiving placebo.
Sustained reduction from early in treatment to final
follow-up occurred in 6.3% of those receiving active
treatment and 1.6% receiving placebo.
Adverse events
Overall, 1384 predominantly middle aged smokers
were treated with nicotine replacement therapy for
six to 18 months and 1383 were treated with placebo.
Four deaths occurred in those randomised to nicotine
replacement therapy and four in those randomised to
placebo:oddsratio1.00 (95% confidenceinterval0.25
to4.02;fig3).Seriousadverseeventsoccurredinfewer
than8%ofparticipantsinbotharms:1.09(0.79to1.50;
fig3).Innocaseswerethesejudgedlikelytohavebeen
due to treatment. Discontinuation of treatment
because of adverse events was rare, with 1.7% in the
nicotine replacement therapy group and 1.3% in the
placebo group: odds ratio 1.27 (0.64 to 2.51; fig 3).
Nausea was selected as an index symptom to indicate
possible nicotine overdose. It was slightly and signifi-
cantlymorecommoninthenicotinereplacementther-
apy group, with 8.6% experiencing nausea compared
with 5.3% in the placebo group: 1.69 (1.21 to 2.36;
fig 3).
DISCUSSION
This review found evidence that nicotine assisted
reduction to stop programmes can be effective in
achieving sustained abstinence from smoking of six
months. There was no evidence of an increase in life
threatening problems, and nicotine replacement ther-
apy was well tolerated, with almost no difference in
discontinuation because of side effects in those
RESEARCH
page 6 of 9 BMJ | ONLINE FIRST | bmj.comreceiving nicotine replacement therapy compared
with those receiving placebo. Nausea was significantly
morecommonwithnicotinereplacementtherapythan
with placebo, but only one in 30 users became
Death
Gum
  Batra (13)
w1
  Haustein (12)w3
  Wennike (24)w5
  Wood-Baker (15)
w6
Inhaler
  Bolliger (24)
w2
  Rennard (15)w4
Mixed
  Etter (26)
w7
Subtotal: I
2=25.7%, P=0.257
Serious adverse events
Gum
  Batra (13)
w1
  Haustein (12)
w3
  Wennike (24)
w5
  Wood-Baker (15)w6
Inhaler
  Bolliger (24)
w2
  Rennard (15)w4
Subtotal: I2=55.3%, P=0.048
Discontinued because of adverse event
Gum
  Batra (13)
w1
  Haustein (12)
w3
  Wennike (24)w5
  Wood-Baker (15)
w6
Inhaler
  Bolliger (24)
w2
  Rennard (15)
w4
Subtotal: I2=0.0%, P=0.636
Nausea
Gum
  Batra (13)
w1
  Haustein (12)w3
  Wennike (24)
w5
  Wood-Baker (15)w6
Inhaler
  Bolliger (24)
w2
  Rennard (15)w4
Subtotal: I2=0.0%, P=0.797
Excluded
Excluded
1.00 (0.06 to 16.12)
0.13 (0.01 to 2.16)
1.00 (0.06 to 16.04)
Excluded
7.53 (0.47 to 120.71)
1.00 (0.25 to 4.02)
1.65 (0.61 to 4.48)
1.41 (0.44 to 4.52)
1.36 (0.56 to 3.26)
0.39 (0.20 to 0.79)
1.61 (0.90 to 2.87)
1.16 (0.54 to 2.49)
1.09 (0.79 to 1.50)
Excluded
Excluded
1.00 (0.14 to 7.19)
2.21 (0.73 to 6.64)
0.67 (0.11 to 3.89)
1.00 (0.32 to 3.13)
1.27 (0.64 to 2.51)
1.74 (0.83 to 3.68)
2.30 (1.16 to 4.56)
1.98 (0.53 to 7.42)
1.31 (0.69 to 2.49)
1.13 (0.43 to 2.98)
2.16 (0.80 to 5.87)
1.69 (1.21 to 2.36)
0/184
0/97
1/205
0/218
1/200
0/215
2/265
4/1384
10/184
7/97
12/205
10/218
32/200
15/215
86/1119
0/184
0/97
2/205
9/218
2/200
6/215
19/184
28/97
6/205
23/218
9/200
11/215
96/1119
0.05 0.25 1 5 20 50
Study (follow-up, months)
Favours
placebo
Favours nicotine
replacement therapy
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Treatment
0/180
0/96
1/206
2/218
1/200
0/214
0/269
4/1383
6/180
5/96
9/206
25/218
21/200
13/214
79/1114
0/180
0/96
2/206
4/218
3/200
6/214
11/180
14/96
3/206
18/218
8/200
5/214
59/1114
Control
No of events/No in group
0.00
0.00
25.00
25.00
24.99
0.00
25.01
100.00
10.14
7.48
13.21
21.34
30.48
17.35
100.00
0.00
0.00
11.94
38.02
14.89
35.16
100.00
19.94
23.86
6.37
26.89
11.79
11.15
100.00
Weight
(%)
Fig 3 | Meta-analysis of safety outcomes; pooled estimates are Peto’s odds ratio (fixed effects). Heterogeneity statistic Q for
death was 4.04 (P=0.257), for serious adverse events was 11.19 (P=0.048), for discontinuation of treatment because of
adverse events was 1.70 (P 0.636), and for nausea was 2.36 (P=0.797). I
2 was 0 (negative value [100×[(Q–DF)/Q)] except for
serious adverse events, where I
2 was 55%
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compared with placebo twice the number of smokers
sustained six months’ abstinence as a result of nicotine
replacement therapy. This equates to about an addi-
tional 3% of all smokers quitting who would otherwise
nothavedoneso.Thisisasimilareffectsizetotreating
smokers who are motivated to quit, where 4-5% might
be expected to abstain for six months owing to use of
nicotine replacement therapy.
13 Previous data suggest
that half of those who sustain six months of abstinence
will maintain it for the rest of their lives.
1415
Three reviews, comprising a Health Technology
Assessment,
10 a Cochrane review,
7 and a qualitative
review
6 have examined smoking cessation achieved
by smokers recruited to randomised controlled trials
of smoking reduction interventions. The present
review is an extension and update of the Health Tech-
nology Assessment report
10 and differs from the
Cochrane review
7 and the qualitative review.
6 We
reportsustainedabstinenceratesderivedfromanalysis
of individual patient data, whereas the Cochrane and
qualitative reviews were restricted to point prevalence
ofsmokingcessationattheendoffollow-up,ameasure
that cannot inform about the duration of cessation,
which is the outcome most relevant to health. Sus-
tained abstinence is the preferred outcome of the
Society for Research in Nicotine and Tobacco
8 and
advised by other experts.
9 We included an additional
trial
w6 not included in the qualitative review. Our
review focused on nicotine replacement therapy
whereasboththeCochraneandthequalitativereviews
encompassedmultipleinterventionsanddidnotmeta-
analyse data on safety outcomes. The qualitative
review concluded that smoking reduction increased
the probability of future cessation, whereas the
Cochrane review concluded that people unwilling to
quit were helped by nicotine replacement therapy to
cut down on number of cigarettes smoked a day. Our
use of sustained abstinence and measurement of safety
has allowed us to draw stronger conclusions on the
public health benefit of smoking reduction with nico-
tine replacement therapy for unwilling quitters.
The licence for nicotine replacement therapy is for
reduction then stopping, whereas the trials in our
review recruited smokers motivated only to reduce
their consumption. We excluded one study in which
participants wanted to quit by reduction,
16 which was
included in both the Cochrane and the qualitative
reviews. The odds ratio for point prevalence of absti-
nence at the end of follow-up from this study was simi-
lar to our pooled effect estimate (2.34, 95% confidence
interval 1.16 to 4.74); this suggests that whether smo-
kers are motivated to reduce then quit or simply moti-
vated to reduce may make little difference to the
efficacy of nicotine replacement therapy in supporting
cessation.Thereisfurtherevidencethatthisdifference
between trial populations (reducers) and the smokers
forwhomtheproductsare marketed(reducingtoquit)
is probably not important. Nearly half of surveyed
American smokers planning to quit would choose
reduction over abrupt cessation, and two thirds of
these were interested in the assistance of drugs.
17 In
these smokers there was little interest in reduction as
an end in itself, only as a means to stop. Even among
those not planning to stop soon, cessation was the goal
for half. Intentions to stop smoking are volatile
18 so a
stated intention to stop at a specified future time may
have little long term meaning for many smokers.
Instructionto stop was delivered in the trials, although
the importance of this instruction has not been tested.
We therefore believe that encouraging smokers pre-
pared to reduce consumption to use nicotine replace-
ment therapy regardless of their subsequent intention
toquitisappropriatebecausethisisthepopulationthat
was included in the trials.
For health services an important issue is whether
nicotine replacement therapy should be reimbursed
in nicotine assisted reduction to stop programmes
and whether and how such programmes should be
implemented. All the industry sponsored trials took
placeinspecialistsmokingcessationclinicswithexten-
sive monitoring and moderate behavioural support.
The remaining trial
w7 was rather analogous to use of
nicotine replacement therapy purchased directly
from retail outlets, but even here a 20 page booklet
was given to participants to motivate and instruct on
reduction. This trial showed lower relative efficacy
than the overall effect estimate and a lower absolute
benefit, but whether this was due to the setting or
chance is unclear.
Currently, nicotine assisted reduction to stop is
licensed in the UK but recent guidance from the
National Institute for Health and Clinical Excellence
and a recent US Clinical Practice Guideline recom-
mend its use only in the context of further
research.
1920 Survey data show that large numbers are
using nicotine replacement therapy to reduce
consumption,
1 but whether they are truly reading the
packet inserts and seeking to follow a nicotine assisted
reduction to stop programme is uncertain. Further-
more, most people who are reducing with nicotine
replacement therapy are using a patch,
1 which is not
licensed for this use and does not come with such
instructions. It is therefore unclear whether the out-
comes observed in the trials are being achieved
through such use.
21
WHAT IS ALREADY KNOWN ON THIS TOPIC
Most smokers are not ready to quit and might not respond to interventions of abrupt
cessation
Nicotinereplacementtherapy(NRT)islicensedforsmokingreductioninsmokersnotreadyto
stop but there is no evidence that it leads to sustained abstinence
No review has assessed the safety of concurrent smoking and use of long term NRT
WHAT THIS STUDY ADDS
This systematic review of randomised clinical trials in smokers not ready to stop found that
with NRT support twice as many quitters achieve six months of sustained abstinence
This equates to an additional 3% of sustained quitters compared with placebo
Using NRT while smoking did not lead to serious health problems
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cept. People who would answer “no” to “do you want
to stop smoking now?” may be helped to stop over a
longer period by applying drugs formerly reserved
only for abrupt cessation. The contribution of the
behavioural support programme is unknown, and the
optimum advice to give people in reduction pro-
grammes is also unknown as these have not been
manipulated in comparative trials. The importance of
these trials is that they show that treating a population
ofsmokersnotreadytostopmeansmoreofthemstop.
Therefore it is important to examine how nicotine
assisted reduction to stop can be incorporated into
tobacco control programmes.
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